Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H7N9 LAIV and IIV Prime-Boost Vaccine Study
NCT02957656Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2016
- Primary completion
- Jun 2018
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of H7N9 pandemic live attenuated influenza vaccine and monovalent inactivated influenza A/H7N9 virus vaccine in avian influenza A H7N9 virus infection (H7N9) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Rates of local and systemic reactogenicity events at Day 264, Development of adverse events at any time point during the study at Day 264 and 4 more. Started Dec 2016; status: completed.
02
Drugs
H7N9 pandemic live attenuated influenza vaccinemonovalent inactivated influenza A/H7N9 virus vaccine
03
Conditions
avian influenza A H7N9 virus infection (H7N9)
Beyond the preview
Go deeper on NCT02957656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957656.